Back to News
Market Impact: 0.2
AbbVie Joins Federal 340B Rebate Pilot Program Ahead Of 2027 Launch
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
AbbVie announced on October 2 that it was approved to participate in the federal 340B Rebate Model Pilot Program. The government initiative is aimed at improving pricing transparency and oversight in the 340B drug discount program; the article excerpt provides no financial terms or expected impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
ABBV0.15
More News
- Mizuho initiates Regenxbio stock coverage with outperform rating
- Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
- AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
- BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
- China shuts hundreds of banks as Beijing moves to shore up its financial system
- Why is NeoGenomics stock sliding today?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What a Concept From Nature Tells Us About How C-Suite Executives Actually Think About AI
- How to Track Earnings Call Sentiment Across Companies